PDCD1 and cancer: While first generation ICI such as anti-programmed cell death protein 1 (PD1), anti-PD1 ligand and anti-cytotoxic T lymphocyte antigen 4 have proven to be effective in some cancers [52], 95% of metastatic CRC are refractory to these immunotherapies [53, 54].